NAOGEN PHARMA S.A.S, created in 2016, develops and produces, with the aim of marketing, a radiopharmaceutical drug, rubidium chloride, produced on demand in nuclear medicine departments by a strontium-rubidium-82 generator. The RUBIGEN ® generator of Naogen Pharma, GMP pharmaceutical laboratory manufacturer, allows the study of cardiac function and myocardial perfusion blood flow in adults with known or suspected coronary artery pathology, by performing Positron Emission Tomography (PET) imaging.
NB: the RUBIGEN ® generator is not authorized by any health agency